Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Launched by MANSOURA UNIVERSITY · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called rifaximin can help prevent diarrhea caused by radiation treatment in cancer patients. Diarrhea is a common side effect of pelvic radiation therapy, which is often used to treat cancers like prostate, bladder, and rectal cancer. The goal of the trial is to see if rifaximin can reduce the chances and severity of this side effect for patients receiving radiation, sometimes along with chemotherapy.

To participate in this trial, individuals need to be 18 years or older and diagnosed with certain types of pelvic cancers. They must be starting radiation treatment with the aim of curing their cancer. However, people with certain medical conditions, such as intestinal issues or those taking specific medications for diarrhea, are not eligible. Participants can expect to receive rifaximin during their treatment and will be monitored to see if it helps them avoid or lessen diarrhea. The trial is still in the planning stage and has not started recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers.
• • Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
• Exclusion Criteria:
• • Patients who have a record of intestinal resection in their medical history.
• • Patients with a medical background of irritable bowel syndrome.
• • Patients with a history of inflammatory bowel disease.
• • Patients who regularly take anti-diarrheal medications before commencing radiotherapy.
• • Patients experiencing diarrhea at the outset of the study.
• • Patients with compromised immune systems, such as those who are HIV positive or using immunosuppressive medications.
• • Pregnant or lactating woman.
• • Patients allergic to rifamycin.